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Objective: Degeneration in cruciate ligaments results from abnormal biomechanical stress and the aging
process. Such degeneration is a common outcome in patients with osteoarthritis (OA) of the knee and
contributes to the progression of OA. However, to date, there are no speciﬁc markers that can predict the
extent of ligament degeneration. We hypothesized that the extent of degeneration has correlations to
increased chondrogenic potential.
Methods: Twenty anterior cruciate ligaments (ACLs) and 30 posterior cruciate ligaments (PCLs) from 30
knees of 28 adult patients with OA at the time of total knee arthroplasty were used for the study.
Degeneration was histologically assessed using a grading system. Expressions of Scleraxis (as a ligament
cell marker) and Sry-type HMG box 9 (SOX9) (as a chondrogenic marker) were immunohistochemically
assessed in each grade.
Results: We found the opposite expression pattern between Scleraxis and SOX9 according to the grade.
The percentage of Scleraxis-positive cells decreased signiﬁcantly by grade (60.9 23.7 in grade 1,
39.7 30.5 in grade 2, and 13.9 27.1 in grade 3, P< 0.0001). In contrast, the percentage of SOX9-
positive cells increased signiﬁcantly by grade (2.5 4.9 in grade 1, 17.5 13.4 in grade 2, and
50.9 27.1 in grade 3, P< 0.0001). Furthermore, co-localized expression of both Scleraxis and SOX9 was
demonstrated in chondrocyte-like cells.
Conclusions: This study indicates that chondrogenic differentiation is associated with the progression of
degeneration in human ligaments. Our results suggest that the expression of SOX9 as a chondrogenic
marker could be an indicator for the extent of degeneration in human ligaments. It remains to be
elucidated whether suppression of chondrogenic differentiation can prevent progression of the degen-
erative process of cruciate ligaments in patients with OA.
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Gradual deterioration of the tissue with corresponding impair-
ment or loss of function is commonly observed in anterior and
posterior cruciate ligaments (ACL and PCL, respectively) with
osteoarthritis (OA) of the knee1e4. Most tendinopathy is associated
with degeneration, which is thought to be an active, cell-mediated
process involving increased turnover and remodeling of extracel-
lular matrix (ECM)5. Such degeneration is thought to contribute to
the development of OA6,7: for example, aging-related factors
contribute to the increased extent of collagen concentration andublished by Elsevier Ltd. All rights reserved.
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Although loss of joint stability in cruciate ligaments is a risk factor
for OA9,10 and severe degeneration of the ACL is more common in
high-grade than low-grade OA11, the biological mechanisms
underlying ligament degeneration have not been well
characterized.
Histologically, degeneration of ligaments is in general charac-
terized by disorganization of collagen ﬁber arrangement, mucoid
changes, chondroid metaplasia, and cystic changes7,11,12. Morpho-
logically, degenerating ligament cells undergo chondrocyte-
patterns such as large round nuclei and/or cells with lacunae.
Alterations in collagen composition, including accumulation of
collagen type III and induction of collagen type II in the ﬁbro-
cartilaginous regions, are also observed in ruptured or degenerat-
ing ligaments13,14.
Scleraxis, a basic helix-loop-helix transcription factor, has been
identiﬁed as a speciﬁc marker of tenogenic cells and mature
differentiated tenocytes15e17. We have shown that mechanical
forces at physiological levels play a critical role in maintaining the
expression of Scleraxis in adult tendon cells through TGF-b/Smad2/
3-mediated signaling18. However, it remains unknownwhether the
expression of Scleraxis in ligaments is altered according to the
extent of degeneration. Furthermore, no studies have addressed
whether cells displaying chondrogenic patterns in degenerating
ligaments induce Sry-type HMG box 9 (SOX9), which is speciﬁcally
expressed in chondrocytes19. We hypothesized that cells in
degenerating ligaments acquire a chrondrogenic potential, thereby
resulting in the downregulation of Scleraxis and upregulation of
SOX9 expression. Here we show persuasive evidence of chondro-
genic differentiation with the degenerative process in cruciate
ligaments.
Materials and methods
Subjects
Twenty ACLs and 30 PCLs were harvested from 30 knees of 28
patients with OA who underwent posterior stabilized total knee
arthroplasty (TKA). The patients comprised 23 female and ﬁvemale
patients (mean age, 77 years; range, 67e84 years). According to the
radiographic grading for osteoarthritic knees20, 10 knees were
grade 3, 14 knees were grade 4, and six knees were grade 5.
Twenty-six knees had varus deformity (femorotibial
angle¼ 186.3 4.9), and four knees had valgus deformity (femo-
rotibial angle¼ 169.37.8). Patients who had a history of knee
injury, previous knee surgery, inﬂammatory arthritis, joint infec-
tion, or immunosuppression therapy were excluded from the study.
The present study was approved by the Institutional Review Board
at the hospital where the TKAs were performed, and informed
consent was obtained from all patients.
Generation of antibody against Scleraxis
DNA coding mouse scleraxis residues (the N-terminal region
before the basic DNA-binding domain) were obtained by PCR using
from whole scleraxis cDNA (pcDNA-SCX, kindly provided by Dr.
Véronique Léjard). We used the N-terminal region before the basic
DNA-binding domain to generate antibody to prevent potential
cross-reactions of antibody with other basic helix-loop-helix
transcription factors. The oligonucleotide primers introduced an
NdeI site at the 50-end and a BamHI site at the 30-end to allow
insertion into the pET15b vector (Novagen). The correct sequence
was conﬁrmed by DNA sequencing. An expression vector was used
for the transformation of E. coli BL21 (DE3: Novagen). A bacterial
pellet was suspended in 8 M urea/10 mM Tris/100 mM sodiumphosphate, pH 8.0, and the recombinant protein was puriﬁed using
Ni-NTA agarose according to the manufacturer’s instructions
(QIAGEN). Immunization of rabbits and afﬁnity-puriﬁcation of
antibodies followed standard protocols21.
Isolation of primary tenocytes from adult mouse tendons and
generation of Scleraxis-null and Scleraxis-expressing tenocyte lines
Although Achilles tendon is the most commonly used tendon
tissue for research in the adult mouse and has the largest ﬁbrous
tissue structure available for analysis, a typical yield of approxi-
mately 1.5104 cells per sample made it impractical to carry out
biochemical observations such asWestern analysis18. Therefore, we
generated Scleraxis-null and Scleraxis-overexpressing tendon lines.
Isolation of tenocytes and establishment of tenocyte cell lines were
described previously18. Brieﬂy, Scleraxis-null tendon cell lines were
generated from Achilles tendon of adult mice on Scleraxis(ﬂ/ﬂ)/p53-
and Scleraxis(ﬂ/ﬂ)p21-null genetic background. Those cells were
isolated and cloned, and several immortalized clones were gener-
ated. Subsequently, several clones were treated with a Cre-trans-
ducing adenovirus to delete the Scleraxis-ﬂoxed genes as
described22. The deletion of Scleraxis alleles was conﬁrmed by PCR
(Scleraxis(ﬂ/ﬂ) mice were kindly provided by Dr. Ronen Schweit-
zer23). For inactivation Scleraxis gene in adult mice, we performed
a single injection of adenovirus encoding Cre recombinase into the
Achilles tendon of adult Scleraxis(ﬂ/ﬂ)mice andwild-typemice24,25.
Oneweek later, the expression of Scleraxis protein in tenocytes was
evaluated by immunohistochemistry.
To generate Scleraxis-expressing tenocyte lines, we generated
a Scleraxis and Flag-tag fusion protein expression construct. Flag-
tag was inserted at the N-terminal site (upstream of the start
codon) or C-terminal site (upstream of the stop codon) of cDNA
encoding Scleraxis and cloned in lentiviral pCDH-CMV-MCS1-Puro
expression vector (pCDH-CMV-MCS-Puro_ScleraxisFlag, System
Biosciences). We used murine cDNA to characterize the speciﬁcity
of the antibody using mouse Scleraxis protein. The sequence
homology between mouse and human Scleraxis cDNA used for
antibody preparation is almost identical (>94% homology): there is
only one amino acid-difference and murine cDNA has three
additional amino acids. For lentivirus production, HEK293T cells
were transfected with pCMV-VSV-G (Addgene plasmid 8454),
pCMV-dR8.2 dvpr (Addgene plasmid 8455), and pCDH-CMV-MCS-
Puro_ScleraxisFlag or pCDH-CMV-MCS-Puro (mock) using lip-
ofectamine (Invitrogen)26. Then lentiviral infection was performed
in Scleraxis-null tendon cells. To generate stable clones, selection
with 10 m/ml puromycin was started at 72 h after transfection, and
the surviving clones were isolated and expanded.
Antibodies and reagents
The following antibodies were used for the analyses: mouse
monoclonal antibody (mAb) against Flag M2 (Sigma, St. Louis, MO,
USA); rabbit polyclonal antibody (pAb) against Scleraxis (described
above); rabbit pAb against SOX9 (Millipore, Temecula, CA, USA);
rabbit pAb against type I collagen (Calbiochem, San Diego, CA, USA),
rabbit pAbs against type II and type III collagen were generated
according to the standard protocols22; rabbit pAb against aggrecan
(Chemicon, Temecula, CA, USA); normal rabbit IgG (Santa Cruz
Biotechnology, Santa Cruz, CA, USA); biotinylated donkey anti-
rabbit IgG and Cy3-conjugated donkey anti-rabbit IgG (Jackson
ImmunoResearch Laboratories,West Grove, PA, USA). The following
reagents were used for the analyses: Vectastain ABC Kit, Vector
ImmPACT VIP substrate kit, and mounting medium containing 406-
diaminido-2-phenylindole (DAPI) (Vector Laboratories, Burlin-
game, California, USA); 303-diaminobenzidine tetrahydrochloride
Fig. 1. The process of sample preparation. Process 1: Cruciate ligaments were excised
from the tibial and femoral attachments (arrowheads). Process 2: Each insertion site
was removed and the mid portion of the ligament (highlighted box) was obtained.
Process 3: The mid portion of the ligament was divided into two tissue fragments: one
was for the preparation of parafﬁn sections (P), the other was for cryosections (C).
Process 4: Longitudinal sections obtained from parafﬁn- and OCT-embedded samples
were used for (immuno)histological stainings: Hematoxylin/eosin, Alcian blue, Scler-
axis, SOX9, and ScleraxiseSOX9 double stainings were performed using parafﬁn-
embedded tissue sections, and type I, type II, and type III collagen, and aggrecan
stainings were performed using OCT-embedded frozen tissue sections. Each staining
was performed using at least ﬁve sections in each sample.
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uronidase (Sigma); chondroitinase ABC (Seikagaku Co., Tokyo,
Japan).
Western blot analysis
For immunoblotting analyses, samples were transferred onto
Immobilon-FL PDVF membrane (Millipore Corp.) and probed with
primary and IRDye 800CW- or IRDye 680-conjugated secondary
antibodies (LI-COR Biosciences, Lincoln, NE, USA). Immunoreactive
bands were detected using the Odyssey Infrared Imaging System
(LI-COR) as described previously22.
Sample preparation and histological analysis
The midvastus muscle-splitting approach was performed
through a standard anteriormidline skin incision for the TKA. Before
resection of the cruciate ligaments, intra-operative macroscopic
assessment of the ACL and the PCL was performed by the surgeon.
Three grades of macroscopic appearance were identiﬁed as previ-
ously described2: grade 0, normal; grade 1, abnormal (thinner than
normal and sclerotic); or grade 2, ruptured (complete disappearance
of the ligament, which is destroyed, or persistence of only a few
ﬁbers). Cruciate ligaments were excised from the tibial and femoral
attachments. Although there are differences in the length, thickness,
and geometry between ACL and PCL27, their histological structure
(including collagen ﬁbril diameter)28,29 and cellular phenotypes30
are quite similar. Therefore, both ACL and PCL were used for the
microscopic analysis. Each insertion site was removed and we got
the mid portion of ligaments, and preserved immediately in 10%
neutral buffered formalin. Half of each ligament sample was then
dehydrated in ascending series of ethanol and embedded in parafﬁn.
The other half was frozen in an optimum cutting temperature (OCT)
compound and stored at 80C. Parafﬁn-embedded samples were
sectioned longitudinally (5 mm thick). The sections were stained
with hematoxylin/eosin or Alcian blue according to the standard
protocols. The process of sample preparation is summarized in Fig.1.
Immunohistochemical analysis
For immunohistochemistry, parafﬁn sectionswerepermeabilized
with 0.2% Triton X-100 for 5 min after the deparafﬁnization step.
Endogenous peroxidase was quenched for 10 min with 3% H2O2 in
water. Nonspeciﬁc binding was blocked with 3% bovine serum
albumin (BSA) in phosphate-buffered saline (PBS). Anti-Scleraxis or
anti-SOX9 antibody was incubated overnight at 4C. The next day,
slides were washed in PBS and incubated with biotinylated anti-
rabbit IgG antibody for 45 min at room temperature. Reaction was
visualized by incubationwith the avidinebiotineperoxidase reagent
included in the Vectastain ABC Kit followed by color development
with DAB. Finally, the sections were counterstained with hematox-
ylin and mounted with coverslips. Normal rabbit IgG was used for
negative control [Fig. 2(C)].
Double-immunohistochemical analysis was performed as
described22. Brieﬂy, the ﬁrst antigen-antibody reaction using anti-
Scleraxis antibody was carried out, and color development was
performed with DAB. The slides were incubated with dissociation
buffer containing 0.1 M glycineeHCl (pH 2.2) to dissociate immu-
noglobulins from antigenic sites. Then the second antigen-antibody
reaction using anti-SOX9 antibody was carried out, and color
development was performed with Vector ImmPACT VIP. We per-
formed the same staining in reverse order, ﬁrst SOX9, then Scler-
axis, and conﬁrmed the same double-positive ﬁndings. We carried
out the second antigen-antibody reaction without antibodies and
conﬁrmed the complete dissociation of the ﬁrst immunoglobulins.For immunoﬂuorescence, longitudinal cryosections (5 mm of
thick) were prepared and washed with PBS. Antigen retrieval was
performed by incubation with 0.2% pepsin in 0.01 N HCl for 30 min
at 37C prior to applying type I collagen antibody, 1 mg/ml hyal-
uronidase in PBS (pH 5.0) for 30 min at room temperature prior to
applying type II collagen antibody, or 1 U/ml chondroitinase ABC in
20 mM TriseHCl buffer solution (pH 8.0) for 2 h at 37C prior to
applying aggrecan antibody. After blocking of nonspeciﬁc binding
with 3% BSA in PBS, primary antibodywas incubated for 1 h at room
temperature. Then slides were washed in PBS and incubated with
Cy3-conjugated donkey anti-rabbit IgG. The slides were mounted
with DAPI to stain the nucleus.
Evaluation of degeneration in cruciate ligaments
Five high-power ﬁelds per each sectionwere randomly captured
using a Leica DMR microscope, with a Qimaging Retiga EXi cooled
CCD camera (Q-Imaging Inc., Burnaby, BC, Canada). Each ﬁeld was
assessed by cellular arrangement and morphological change of cell
nuclei. Following three-point scoring system was used in
two variables with a modiﬁcation of previously described
methods11,12,31,32:
Fig. 2. Speciﬁcity of Scleraxis antibody. (A) Western blot analysis of lysates from Scleraxis-null, mock-transfected, and Scleraxis/N-terminal ﬂag fusion protein transfected cells. The
position of a molecular mass marker (kDa) is indicated. b-actin served as a loading control. (B) Immunoﬂuorescence staining for Scleraxis of the Achilles tendon in wild-type (upper
panel) and Scleraxis(ﬂ/ﬂ) (lower panel) mice at 7 days after local injection of adenovirus-Cre (red, Scleraxis; blue, DAPI). Scale bar¼ 50 mm. (C) Immuohistochemical stainings in
human cruciate ligament using anti-Scleraxis antibody (left panel) and normal rabbit IgG (right panel, as a negative control). Note that no background staining is conﬁrmed in the
section using normal rabbit IgG. Scale bar¼ 25 mm.
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The angles between the long axis in each cell and the direction
of collagenous ﬁbers weremeasured. The scoring point in each ﬁeld
was determined as follows:
Point 0: less than 10 degrees of alignment in all cells examined.
1: 11e45 degrees of alignment in less than 50% cells and less
than 10 degrees of alignment in the rest.
2: over 10 degrees of alignment in more than 50% cells or
existence of cells with over 45 degrees of alignment.
In case of completely round cells, we could not deﬁne a cellular
axis and scored such cells as point 2. We also scored point 2 when
the ﬁber direction was lost.
For the assessment of morphological changes in the cell nuclei:
Point 0: no appearance of round nuclei.
1: <50% appearance of round nuclei.
2: 50% appearance of round nuclei.
When 0 points were scored in both variables or 1 point was
scored in either of the variables, the ﬁeld was deﬁned as grade 1.
When abnormal changes (1 or 2 points) were scored in both vari-
ables and 2 points were scored in at least 1 variable, the ﬁeld wasdeﬁned as grade 3. Consequently, each ﬁeld was graded by the total
score: Total score 0 or 1¼ grade 1; Total score 2¼ grade 2; Total
score 3 or 4¼ grade 3. For the assessment of degenerative grade, we
examined at least ﬁve different high-power ﬁelds in each ligament
and calculated each parameter: all cells in each ﬁeld were analyzed
for cell density, cellular arrangement, and morphological changes.
Two independent observers assessed degenerative grade. The
kappa coefﬁcient value in the grading score was 0.79, indicating
good agreement for inter-observer reproducibility.
Quantiﬁcation of labeled cells
The number of total cells and Scleraxis- and SOX9-positive cells
were counted, then the positive cell ratio was calculated in each
ﬁeld. The results were compared among the grades of
degeneration.
Statistical analysis
The mixed-effects model was used to investigate the relation-
ship of the cell density and the markers with the grade because of
the non-independence of the multiple measurements from the
same patient. When a signiﬁcant difference of the cell density
among the grades was detected by the mixed-effects model, the
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formed. To conﬁrm the linear relationship between the grade and
the markers, we tested the slope of the grade as a continuous
variable in the mixed-effects model. A chi-square test was per-
formed to analyze the distribution of grades between ACL and PCL.
P value< 0.05 was considered statistically signiﬁcant. All data were
expressed as mean standard deviation (SD). Analysis was done
using SigmaStat 3.5 software (Systat Software Inc., Richmond, CA,
USA) and SAS 9.3 (SAS Institute Inc., Cary, NC, USA).
Results
Speciﬁcity of Scleraxis antibody
We ﬁrst characterized our Scleraxis antibody by Western anal-
ysis. Scleraxis antibody did react with lysates from cells expressing
Scleraxis/N-terminal ﬂag fusion proteins with an apparent molec-
ular mass of w30 kDa under reducing conditions, but it did not
react with lysates from Scleraxis-null or mock-transfected cells
[Fig. 2(A)]. Furthermore, the molecular size of the reacted band was
completely identical to that detected with anti-ﬂag antibody from
cells expressing Scleraxis/N-terminal ﬂag fusion proteins [Fig. 2(A),
arrowhead]. Immunoﬂuorescence analysis of adult mouse Achilles
tendons further conﬁrmed considerably decreased expression of
Scleraxis in Cre-treated Scleraxis(ﬂ/ﬂ) tendon cells, whereas intense
Scleraxis protein expression was evident in wild-type tenocytes
[Fig. 2(B)]. These ﬁndings indicate that our Scleraxis antibody
speciﬁcally detects Scleraxis proteins.
Macroscopic appearance of cruciate ligaments in arthritic knees
We obtained 20 ACLs and 30 PCLs. Macroscopic ﬁndings are
summarized in Table I. They consisted of nine normal, 11 thin and
sclerotic, and 10 ruptured samples from ACLs; 22 normal, and eight
thin and sclerotic samples from PCLs. There were no macroscopi-
cally ruptured PCLs on intra-operative inspection. Ruptured ACLs in
10 knees were excluded from this study due to complete loss of the
ligament or persistence of only a few ﬁbers.
Histology of degenerating cruciate ligament
For histological evaluation, each ﬁeld was graded in terms of
cellular alignments, and cellular shapes (i.e., spindle or round)
[Fig. 3(A), Table II]. Cruciate ligaments obtained from OA patients
revealed a highly variable collagen ﬁber arrangement and cellular
morphology. Thirty-seven of 250 ﬁelds (14.8%) were classiﬁed as
grade 1, characterized with parallel ﬁber arrangement, including
82% of spindle-shaped cell nuclei. Eighty-seven ﬁelds (34.8%) were
classiﬁed as grade 2 and 126 ﬁelds (50.4%) were classiﬁed as grade
3. ACL consisted of 12% grade 1, 36% grade 2, and 52% grade 3, and
PCL consisted of 17.3% grade 1, 33.3% grade 2, and 49.3% grade 3.
Therewere no signiﬁcant differences of grade distribution between
ACL and PCL (P¼ 0.57, chi-square test). As the grade increased,
collagenous ﬁbers lost the orientation of parallel alignment, and
nuclei became round, revealing the possible chondrogenicTable I
Classiﬁcation of grades according to macroscopic ﬁndings of cruciate ligaments in
OA knees
Grade ACL PCL
0 (Normal) 9 (30) 22 (73.3)
1 (Abnormal) 11 (36.7) 8 (26.7)
2 (Ruptured) 10 (33.3) 0 (0)
Values represent the number of knees and (%).differentiation. Cruciate ligaments in grade 3 almost completely
lost parallel ﬁber arrangement, and round cell shapes with round
nuclei resembling those of chondrocytes were often observed.
Next, cell density in each grade was calculated to assess the
number of cells (Table II). The mean cell density was 349179/
mm2 in grade 1 (n¼ 37), 460 328/mm2 in grade 2 (n¼ 87), and
361199/mm2 in grade 3 (n¼ 126). The statistical tests using
a mixed-effects model and a post hoc all-pairwise multiple
comparison showed a signiﬁcant difference between grades 2 and 3
(P< 0.05, TukeyeKramer test).
Immunoﬂuorescence of collagen type I and III
To assess collagen content in ECM associated with degeneration,
we examined localization of collagen type I and III by immunoﬂu-
orescence ﬁndings [Fig. 3(B)]. The collagen type I, a predominant
constituent in tendons/ligaments5, was conﬁrmed in most of the
ECM. The prevalence of collagen type I was similar among grades.
The deposition of collagen type III was sometimes observed as foci
in the ECM surrounding round cells in early stages of degeneration,
and this deposition of collagen type III was preserved in advanced
stages of degeneration, suggesting active remodeling reactions in
these cells during chronic degeneration process5.
Immunohistochemical analysis of Scleraxis
To identify expression of tendons/ligaments speciﬁc marker in
degenerating cruciate ligaments, we performed immunostaining
for Scleraxis. Each image was graded, and the number of Scleraxis-
positive cells was measured [Fig. 4(A)]. The percentage of Scleraxis-
positive cells/total cells in each grade was 60.9 23.7% in grade 1
(n¼ 47), 39.730.5% in grade 2 (n¼ 105), and 13.9 27.1% in grade
3 (n¼ 98) (P< 0.0001 among grades), and decreased according to
the grade of degeneration (slope, 17.3; P< 0.0001) [Fig. 4(B), left].
Of the Scleraxis-positive cells, 65.2% had spindle-shaped nuclei and
34.8% had round nuclei. Furthermore, the compositions of spindle-
shaped vs round nuclei in each grade were 83.5%/16.5% in grade 1
(n¼ 46), 64.9%/35.1% in grade 2 (n¼ 77), and 50.9%/49.1% in grade 3
(n¼ 49) (slope, 16.1; P< 0.0001) [Fig. 4(B), right]. These ﬁndings
revealed that the ratio of round nuclei in Scleraxis-positive cells
increased with grade of degeneration, suggesting possible sus-
tained expression in early stages of the chondrogenic differentia-
tion process.
Immunohistochemical analysis of SOX9
To investigate the chondrogenic potential in degenerating
cruciate ligaments, we performed immunostaining for SOX9. Each
ﬁeld was graded, and the number of SOX9-positive cells was
measured [Fig. 4(C)]. The percentage of SOX9-positive cells/total
cells was 2.5 4.9% in grade 1 (n¼ 44), 17.513.4% in grade 2
(n¼ 79), and 50.9 27.1% in grade 3 (n¼ 127) (P< 0.0001 among
grades), and increased according to the grade of degeneration
(slope, 22.5; P< 0.0001) [Fig. 4(D), left]. Expression of SOX9 was
observed in 21.0% of cells with spindle-shaped nuclei and 79.0% of
cells with round nuclei. Of the SOX9-positive cells, the composi-
tions of spindle-shaped vs round nuclei in each grade were 62.8%/
37.2% in grade 1 (n¼ 14), 31.4%/68.6% in grade 2 (n¼ 66), and 16.1%/
83.9% in grade 3 (n¼ 121) (slope, 17.3; P< 0.0001) [Fig. 4(D), right].
Co-localized expression of Scleraxis and SOX9
To examine whether ligament cells expressing Scleraxis have
chondrogenic potential,weperformeddouble-immunohistochemical
staining for Scleraxis and SOX9. Co-localized expression of both
Fig. 3. Representative histopathological ﬁndings in degenerating cruciate ligaments. (A) Typical morphological patterns in grade 1e3. Grade 1 represents normal or slight
degeneration, and grade 3 represents most advanced degeneration. Parallel cellular arrangement reduces but the number of cells with round nuclei (arrowheads) increases in
accordance with the grade of degeneration. Hematoxylin/eosin staining. Upper panels: low magniﬁcation. Scale bar¼ 100 mm. Lower panels: higher magniﬁcation. Scale
bar¼ 25 mm. (B) Immunoﬂuorescence staining for collagen type I and III in grades 1e3. Upper panels: collagen type I (red) and nuclear staining with DAPI (blue). The tissue
distribution of collagen type I is similar in each grade. Lower panels: collagen type III (red) and DAPI (blue). Foci of collagen type III are shown surrounding round cells in grade 2
(arrowheads), and several deposition foci are preserved in the ECM in grade 3 (arrowheads). Scale bar¼ 25 mm.
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(Fig. 5).Immunoﬂuorescence of collagen type II and aggrecan
To further address the chondrogenic potential in degenerative
ligaments, we examined the deposition of collagen type II, a major
component of cartilage ECM. Focal and scattered spot-like deposi-
tions of collagen type II were found in the ECM surrounding roundTable II
The number of assigned ﬁelds and themean cell density in each histological grade of
cruciate ligaments
Grade 1 Grade 2 Grade 3
Number of ﬁelds 37 (14.8%) 87 (34.8%) 126 (50.4%)
Cell density (cells/mm2)* 349 179 460 328y 361 199y
* Values represent mean SD.
y Signiﬁcant difference between grade 2 and grade 3 (P< 0.05).cells with round nuclei [Fig. 6(A), upper panels]. Weak expression
of aggrecanwas also observed in the ECM surrounding those round
cells [Fig. 6(A), lower panels]. These deposition and localization
patterns of collagen type II and aggrecan suggest that a chondro-
genic potential was induced in the ECM with increasing degener-
ation. In addition to identiﬁcation of collagen type II and aggrecan,
Alcian blue-positive areas were found in the ECM surrounding the
round cells, conﬁrming the accumulation of glycosaminoglycans
[Fig. 6(B)].
Discussion
The major advances in the present study are the assessment of
a relationship between 1) the histological grade of degeneration
and chondrogenic differentiation with the speciﬁc marker SOX9,
and 2) the histological grade of degeneration and Scleraxis
expression levels. We have demonstrated decreased numbers of
Scleraxis-positive cells and increased numbers of SOX9-positive
cells according to the histological grade of degeneration. We
Fig. 4. Expression patterns of Scleraxis and SOX9 in each grade of degeneration. (A, B) Immuohistochemical staining for Scleraxis in grades 1e3. (A) Arrowheads indicate Scleraxis-
positive cells (brown). Scale bar¼ 25 mm. Note that positive staining is shown in both nucleus and cytoplasm (inset). (B) Left panel: percentage of Scleraxis-positive cells. Grade 1;
n¼ 47, grade 2; n¼ 105, grade 3; n¼ 98. Values are given as mean SD. Right panel: percentage of spindle-shaped/round nuclei in Scleraxis-positive cells. Grade 1; n¼ 46, grade 2;
n¼ 77, grade 3; n¼ 49. Values are given as mean SD. *P< 0.05. (C, D) Immunohistochemical staining for SOX9 in grades 1e3. (C) Arrowheads indicate SOX9-positive cells (brown).
Scale bar¼ 25 mm. Note that positive staining is shown in both nucleus and cytoplasm (inset). (D) Left panel: percentage of SOX9-positive cells. Grade 1; n¼ 44, grade 2; n¼ 79,
grade 3; n¼ 127. Values are given as mean SD. Right panel: percentage of spindle-shaped/round nuclei in SOX9-positive cells. Grade 1; n¼ 14, grade 2; n¼ 66, grade 3; n¼ 121.
Values are given as mean SD. *P< 0.05.
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Fig. 5. Co-localized expression of Scleraxis and SOX9. (A) Double-immunohistochemical staining for Scleraxis and SOX9 (from grade 2 sample). Scleraxis (light brown) is co-
localized with SOX9 (dark purple) in chondrocyte-like cells (black arrowheads). Scale bar¼ 25 mm. Inset: cellular co-localization of Scleraxis (white arrowheads) and SOX9
(white arrow). (B) The same staining procedures shown in (A) without second antigen-antibody reaction (from grade 2 sample). Positive cells express only Scleraxis (light brown) as
the ﬁrst antigen-antibody products. Scale bar¼ 25 mm. Inset: cellular distribution of Scleraxis (both nucleus and cytoplasm).
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ation of cells in degenerative ligaments.
Several studies indicate structural/morphological changes in
degenerative human ligaments: they show the disorganization of
ﬁber arrangements and the presence of chondrocyte-like
cells7,11,12,33. Indeed, in tendon degeneration models such as the
rat collagenase-induced patellar tendon degeneration model,
approximately 5% of degenerating areas show calciﬁc foci, in which
chondrocyte-like cells expressing collagen type II and SOX9 are
observed around those foci19. However, to date, no studies have
shown alterations in expression proﬁles of ligament and chon-
drocyte markers in those cells during the progression of ligament
degeneration. Here we have provided evidence that the number of
SOX9-positive chondrocyte-like cells actually increase signiﬁcantly
according to human ligament degeneration with cartilage-speciﬁc
collagen type II and aggrecan depositions. Thus, our ﬁndings
suggest that chondrogenic differentiationmay play a key role in the
progression of ligament degeneration and that the number of
SOX9-positive cells could be a potential indicator to determine the
extent of degeneration in ligaments.
We suggest possible mechanisms for decreased number of
Scleraxis-positive cells in degenerative ligaments. First, there is
evidence that the expression of Scleraxis depends on the levels of
physical forces: the loss of tensile loading from skeletal muscles in
the mouse Achilles tendon complete transection model immedi-
ately and signiﬁcantly downregulates Scleraxis expression in
tendon cells18. Furthermore, several studies using intact human
knees (femur-ACL-tibia complex) have shown that the biome-
chanical properties of the knees such as strength and stiffness, are
signiﬁcantly reduced with increasing age34,35. Although no studies
have demonstrated direct evidence showing decreased biome-
chanical properties in degenerative ligaments, these ﬁndings
suggest that both aging and alterations of physical forces could
contribute to the downregulation of Scleraxis expression and the
degenerative process in ligaments. Secondly, decreased cellular
densities are observed in advanced human rotator cuff degenera-
tion, and apoptosis plays an important role in this degenerative
process31,36. Therefore, as we previously found in mouse tendon
injury models18, it is likely that the downregulation of Scleraxis
expression levels can contribute to a cell-death cascade in degen-
erative ligaments.Recent ﬁndings from developing embryos illuminate the recip-
rocal interactions among the forming tendon/ligament, muscle and
cartilage tissues37,38. Although chondrogenic differentiation is
regulated by the interaction between Scleraxis and SOX939, several
studies show functional correlations between the loss of Scleraxis
and the upregulation of SOX9 in the transdifferentiation of liga-
ment/tendon cells to chondrocyte-like cells: cultured ACL-derived
cells acquire a chondrogenic property with SOX9 expression
under chondrogenesis-induction medium40. Moreover, Takimoto
et al.41 have demonstrated that overexpression of SOX9 induced the
direct conversion of tenocytes into chondrocytes with down-
regulation of Scleraxis expression in vitro. Thus, the loss of Scler-
axis-positive cells in degenerative ligaments may be due to
transdifferentiation of tendon cells into chondrocyte-like cells.
Importantly, we have demonstrated in the present study the cells
expressing both Scleraxis and SOX9 in degenerative human liga-
ments, which suggests that even mature ligament cells have
a chondrogenic potential with the process of degeneration.
One limitation of this study could be the absence of normal
samples (no degenerative changes). The mean age of subjects in the
present study is relatively old (77 years, range 67e84). Indeed, the
extent of degeneration in cruciate ligaments increases with age7.
Therefore, even if we obtained samples from healthy people of the
same age as those in the present study, they could not be used as
normal controls. The focus of the current study is to identify the
variation of cellular events with degeneration, and the results
presented here are sufﬁcient to justify our conclusions.
This study provides insights into themodulation of Scleraxis and
SOX9 expression in the process of ligament degeneration. Chon-
drogenic differentiation is critical to provoke and progress degen-
eration in ligaments19,42. Therefore, expression of SOX9 as
a chondrogenic marker could be an indicator of the extent of
degeneration in ligaments. Our work strongly suggests that the
increased expression levels and the maintenance of Scleraxis-
positive cells could be promising factors to improve the prognosis
in degenerating ligaments as well as healing in injured ligaments18.
OA is a serious clinical problem because it is a major cause of
disability, particularly in older patients. It remains to be elucidated
whether suppression of chondrogenic differentiation can prevent
progression of the degenerative process of cruciate ligaments in
patients with OA.
Fig. 6. Immunoﬂuorescence staining for collagen type II and aggrecan, and Alcian blue staining in degenerating cruciate ligaments. (A) Expressions of collagen type II and aggrecan
in grades 1e3. Upper panels: collagen type II (red) and nuclear staining with DAPI (blue). Lower panels: aggrecan (red) and DAPI (blue). Note that focal and scattered spot-like
depositions of collagen type II and aggrecan are shown in the ECM surrounding round cells in grades 2 and 3 (arrowheads). Scale bar¼ 50 mm. (B) Alcian blue staining from
the grade 2 sample. Upper panels: Alcian blue staining. Lower panels: hematoxylin/eosin staining. Strong reactions (blue) are evident in the ECM around round cells (arrowheads).
Scale bar¼ 100 mm (left panels) and 25 mm (right panels).
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